Two Chemotherapy Regimens Plus or Minus Bevacizumab

Inclusion criteria

• ✓. Disease accessible to resection or percutaneous method of destruction
• ✓. Any known allergy or contraindication to the treatments used in the trial
• ✓. Patients with a complete DPD deficiency; defined as an uracil concentration ≥150ng/ml Note: patients with a suspicion of partial DPD deficiency, defined as a uracil concentration ≥ 16 ng/ml and \< 150 ng/ml, will receive an adapted 1st cycle dose, according to a clinic-biological discussion. The dose can be then readapted for the second cycle according to the tolerability of the treatment during the 1st cycle.
• ✓. Patient previously treated with chemotherapy for the neuroendocrine tumour
• ✓. Patient have received any other antitumor therapy: chemotherapy, immunotherapy
• ✓. Other serious diseases such as respiratory failure or congestive heart failure, angina pectoris not medically controlled; history of myocardial infarction within 6 months prior to study entry, uncontrolled hypertension and arrhythmias, concomitant severe infection or uncontrolled diabetes mellitus
• ✓. Subjects with a history of chronic or acute hepatitis C or B infection.
• ✓. Surgery during the 5 weeks preceding the randomization